Goal
Treat cancer by inhibiting oncogenes, promoting apoptosis, and activating tumor-suppressor genes.
Problem
Various cancers and chemotherapy-induced fatigue/toxicity.
Concept Summary
Antineoplastons are a group of peptide-derived compounds (e.g., A-10, AS2-1, phenylacetylglutamine) administered intravenously or orally to cancer patients. The therapy claims anti-cancer activity by modulating oncogenic pathways, DNA-methylation enzymes, and histone deacetylases. Formulations include plain mixtures and liposomal delivery systems that allegedly increase cellular uptake and antineoplastic potency.
Principles
- Peptide-based drug therapy
- Oncogene inhibition
- Apoptosis induction
- Tumor-suppressor gene activation
- Histone deacetylase (HDAC) inhibition
- Liposomal drug delivery
Scientific Domains
Materials
- Phenylacetylglutamine
- Phenylacetic acid
- Phenylacetylisoglutamine
- Phenylbutyrate
- Riboflavin
- Essential and non-essential amino acids
- Silica (as abrasive in toothpaste formulation)
- Liposome carriers
Mechanisms of Action
- Inhibition of oncogenic enzymes
- Promotion of programmed cell death
- Activation of p21 and p53 tumor-suppressor pathways
- Weak inhibition of HDAC by phenylacetic acid
- Alteration of DNA-methylation enzyme activity
Applications
- Cancer treatment
- Alleviation of chemotherapy-induced fatigue
Claimed Performance
Liposomal formulations increase in-vitro antineoplastic activity by a factor of 750-1500 and cellular uptake by 30-80-fold compared with non-liposomal antineoplastons.
Experimental Evidence
Laboratory studies have shown inhibition of DNA-methylation enzymes and weak HDAC inhibition; however, independent tests at the National Cancer Institute and the Japanese National Cancer Institute reported no positive anti-cancer effects.
Replication Status
No independent replication of clinical efficacy reported.
Limitations
- Not FDA-approved
- High treatment cost (> $100,000 per year)
- Lack of peer-reviewed positive clinical data
- Potential sodium overload requiring careful electrolyte management
Red Flags
- Independent studies have failed to demonstrate efficacy
- Financial conflict of interest (clinic trades as penny stock)
- Claims of anti-cancer activity without robust, peer-reviewed data
